Catalio Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Catalio Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.27M	Buy	+471,254	New	+$4.59M	1.18%	27

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Catalio Capital Management's FDMT Position: Q2 2026 in Review

Catalio Capital Management opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 471,254 shares worth $6.27M. The stake represents 1.18% of the portfolio and ranks #27 among its holdings.

158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Catalio Capital Management held 471,254 shares of 4D Molecular Therapeutics worth $6.27M as of Q2 2026.
4D Molecular Therapeutics was a new Catalio Capital Management position in Q2 2026.
4D Molecular Therapeutics made up 1.18% of Catalio Capital Management's portfolio in Q2 2026, its #27 holding.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Catalio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.